Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted on February 2, 2026 to two new employees under its 2024 Inducement Plan. The Compensation Committee granted non‑qualified stock options for 11,500 shares and RSUs for 5,750 shares.

Each option’s exercise price equals $45.28 (closing price on February 2, 2026). Options vest over four years with 25% after one year then monthly over 36 months; RSUs vest 25% on each anniversary of February 20, 2026, subject to continued service and plan terms.

Key Figures

Stock options granted: 11,500 shares RSUs granted: 5,750 shares Option exercise price: $45.28 +5 more

8 metrics

Stock options granted 11,500 shares Non-qualified options under 2024 Inducement Plan

RSUs granted 5,750 shares Restricted stock units to two new employees

Option exercise price $45.28 Equal to closing price on February 2, 2026

Option vesting schedule 4 years (25% then 36 months) 25% at year one, remainder monthly over 36 months

RSU vesting period 4 years 25% on each anniversary of February 20, 2026

Current share price $40.95 Pre-news price, down 4.19% over 24 hours

52-week range $18.53–$56.05 Price is 26.94% below 52-week high, 120.99% above low

Market capitalization $3,033,979,679 Value prior to this inducement grant announcement

Market Reality Check

Price: $43.50 Vol: Volume 1,180,322 is 1.11x...

normal vol

$43.50 Last Close

Volume Volume 1,180,322 is 1.11x the 20-day average of 1,066,226 shares. normal

Technical Trading above 200-day MA at $29.79 while shares sit 26.94% below the 52-week high.

Peers on Argus

VERA fell 4.19% while key biotech peers like AUPH (-1.59%), VRDN (-3.38%), ARDX ...

VERA fell 4.19% while key biotech peers like AUPH (-1.59%), VRDN (-3.38%), ARDX (-3.85%), and EWTX (-3.58%) also declined, but no peers showed momentum scanner signals or same-day news linkage, pointing to a stock-specific move.

Historical Context

5 past events · Latest: Jan 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 28	Management appointment	Positive	-3.5%	New Chief Commercial Officer appointed to lead atacicept launch readiness.
Jan 9	Inducement grants	Neutral	+2.1%	Equity inducement awards to 18 new employees under 2024 Inducement Plan.
Jan 8	Conference participation	Neutral	-2.0%	Participation and webcast at J.P. Morgan Healthcare Conference announced.
Jan 7	FDA priority review	Positive	+4.6%	FDA accepted BLA for atacicept and granted Priority Review for IgAN.
Dec 9	Equity offering	Negative	-0.8%	Underwritten public offering of Class A stock priced with expected dilution.

Pattern Detected

Recent news has mostly aligned with price reactions, with only one divergence on a positive management update.

Recent Company History

Over recent months, Vera’s key milestones included an FDA Priority Review and Accelerated Approval pathway for atacicept in IgA nephropathy on Jan 7, 2026, which coincided with a 4.64% gain. Capital-raising via a December 2025 equity offering saw a modest negative reaction. Administrative items such as conference participation, inducement grants, and leadership changes produced mixed but generally moderate moves. Today’s small inducement grant update fits this pattern of routine corporate housekeeping news.

Market Pulse Summary

This announcement details routine inducement equity awards to two new employees: options on 11,500 s...

Analysis

This announcement details routine inducement equity awards to two new employees: options on 11,500 shares at a $45.28 exercise price and 5,750 RSUs, both vesting over four years. It follows a larger January 2026 inducement grant round and recent regulatory and capital markets activity. Investors may monitor how ongoing hiring, insider filings, and future atacicept milestones interact with this growing compensation overhang and the company’s broader dilution history.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, restricted stock units (rsus), exercise price

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"granted inducement awards... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"inducement awards consisting of non-qualified stock options to purchase 11,500 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units (rsus) financial

"and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

exercise price financial

"Each stock option granted on February 2, 2026 has an exercise price per share equal to $45.28"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

BRISBANE, Calif., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on February 2, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 11,500 shares of Class A common stock and restricted stock units (RSUs) underlying 5,750 shares of Class A common stock to two (2) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on February 2, 2026 has an exercise price per share equal to $45.28, Vera Therapeutics’ closing trading price on February 2, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of February 20, 2026, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109 and MAU868. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors 212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth Vera Therapeutics 415-854-8051
corporatecommunications@veratx.com

FAQ

What inducement awards did Vera Therapeutics (VERA) grant on February 2, 2026?

Vera Therapeutics granted non‑qualified stock options for 11,500 shares and RSUs for 5,750 shares to two new employees. According to Vera Therapeutics, the grants were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

What exercise price was set for VERA stock options granted on February 2, 2026?

Each option has an exercise price of $45.28, equal to Vera Therapeutics’ closing price on February 2, 2026. According to Vera Therapeutics, the exercise price was set to match the market close on the grant date.

How do the VERA option and RSU vesting schedules work for the February 2, 2026 grants?

Options vest over four years: 25% after one year, then monthly over 36 months; RSUs vest 25% on each anniversary of February 20, 2026. According to Vera Therapeutics, vesting is subject to continued service through each vesting date.

Why did Vera Therapeutics (VERA) use inducement awards under Nasdaq Listing Rule 5635(c)(4)?

The Compensation Committee approved the awards as inducements materially related to new employees’ employment, in line with Nasdaq Listing Rule 5635(c)(4). According to Vera Therapeutics, the grants were made to induce the two new hires to join the company.

Are the February 2026 VERA awards subject to additional terms or conditions?

Yes, the awards are subject to the Vera Therapeutics 2024 Inducement Plan and applicable award agreements containing detailed terms. According to Vera Therapeutics, each grant is governed by the plan and the individual award agreement terms.